5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | SELL | SELL | SELL | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 77.63▲ | 77.73▼ | 77.76▼ | 78.80▼ | 79.97▼ |
MA10 | 77.60▲ | 77.76▼ | 77.77▼ | 80.11▼ | 76.80▲ |
MA20 | 77.66▲ | 77.79▼ | 77.78▼ | 80.24▼ | 73.76▲ |
MA50 | 77.74▼ | 78.18▼ | 79.48▼ | 76.22▲ | 71.77▲ |
MA100 | 77.76▼ | 79.59▼ | 80.16▼ | 73.48▲ | 72.07▲ |
MA200 | 77.78▼ | 80.14▼ | 79.20▼ | 71.91▲ | 68.72▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.010▲ | 0.035▲ | 0.105▲ | -0.693▼ | 0.816▲ |
RSI | 51.936▲ | 44.383▼ | 37.714▼ | 43.738▼ | 56.301▲ |
STOCH | 61.105 | 51.560 | 68.555 | 24.922 | 86.923▲ |
WILL %R | -3.704▲ | -39.572 | -39.572 | -89.269▼ | -34.070 |
CCI | 134.873▲ | -78.252 | -68.962 | -141.230▼ | 47.992 |
Wednesday, September 17, 2025 08:22 AM
AstraZeneca (NASDAQ:AZN) said that the late-stage trial for its medication Fasenra (benralizumab) in patients suffering from chronic obstructive pulmonary disease did not meet primary endpoint. The ...
|
Wednesday, September 17, 2025 07:27 AM
AstraZeneca (NASDAQ:AZN) announced on Wednesday that a Phase 3 trial for an injectable version of Saphnelo (anifrolumab), its FDA-approved therapy for an autoimmune disorder called systemic lupus ...
|
Wednesday, September 17, 2025 12:55 AM
AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
17/09/25 | 77.175 | 78.08 | 77.145 | 77.71 | 4,360,003 |
16/09/25 | 77.91 | 78.02 | 77.24 | 77.56 | 3,409,475 |
15/09/25 | 78.22 | 78.52 | 77.365 | 78.05 | 4,447,216 |
12/09/25 | 80.82 | 81.16 | 79.08 | 79.56 | 4,491,748 |
11/09/25 | 80.82 | 81.306 | 80.68 | 81.10 | 2,829,735 |
10/09/25 | 80.91 | 81.12 | 80.575 | 80.81 | 2,112,545 |
09/09/25 | 81.005 | 81.36 | 80.74 | 81.22 | 2,379,148 |
08/09/25 | 80.73 | 81.605 | 80.18 | 81.56 | 2,624,015 |
05/09/25 | 82.05 | 82.41 | 81.54 | 81.70 | 2,464,583 |
04/09/25 | 81.88 | 82.28 | 81.48 | 81.78 | 3,121,637 |
|
|
||||
|
|
||||
|
|